Telomerase is a specialized reverse transcriptase containing an intrinsic telomerase RNA (TR) which provides the template for telomeric DNA synthesis. Distinct from conventional reverse transcriptases, telomerase has evolved a unique TR-binding domain (TRBD) in the catalytic telomerase reverse transcriptase (TERT) protein, integral for ribonucleoprotein assembly. Two structural elements in the vertebrate TR, the pseudoknot and CR4/5, bind TERT independently and are essential for telomerase enzymatic activity. However, the details of the TR-TERT interaction have remained elusive. In this study, we employed a photoaffinity cross-linking approach to map the CR4/5-TRBD RNA-protein binding interface by identifying RNA and protein residues in close proximity. Photoreactive 5-iodouridines were incorporated into the medaka CR4/5 RNA fragment and UV cross-linked to the medaka TRBD protein fragment. The cross-linking RNA residues were identified by alkaline partial hydrolysis and cross-linked protein residues were identified by mass spectrometry. Three CR4/5 RNA residues (U182, U187, and U205) were found cross-linking to TRBD amino acids Tyr503, Phe355, and Trp477, respectively. This CR4/5 binding pocket is distinct and separate from the previously proposed T pocket in the Tetrahymena TRBD. Based on homologous structural models, our cross-linking data position the essential loop L6.1 adjacent to the TERT C-terminal extension domain. We thus propose that stem-loop 6.1 facilitates proper TERT folding by interacting with both TRBD and C-terminal extension. Revealing the telomerase CR4/5-TRBD binding interface with single-residue resolution provides important insights into telomerase ribonucleoprotein architecture and the function of the essential CR4/5 domain.
T elomerase maintains telomere length through de novo synthesis of telomeric DNA repeats onto chromosome ends. Telomeres function to distinguish native chromosome ends from double-strand breaks (1) . Cells lacking active telomerase exhibit progressive telomere shortening and reduced replicative capacity. Mutations in telomerase genes cause telomerase deficiency, leading to telomere attrition and a number of human diseases including dyskeratosis congenita, aplastic anemia, and idiopathic pulmonary fibrosis (2) . Furthermore, telomerase is activated in the vast majority of cancer cells, bypassing senescence induced by critically short telomeres (3) . Understanding the mechanism and architecture of telomerase is thus essential for the development of therapies for telomere-mediated diseases.
Unlike conventional reverse transcriptase (RT), telomerase functions as a ribonucleoprotein (RNP) containing a catalytic telomerase reverse transcriptase (TERT) and the telomerase RNA (TR) (4). TERT comprises four major structural domains: the telomerase essential N terminus (TEN) domain, the telomerase RNA-binding domain (TRBD), the RT domain, and the C-terminal extension (CTE) domain. In addition to providing the template for DNA synthesis, the TR contains two highly conserved structural domains: the template-proximal pseudoknot structure that forms a triple helix and the three-way helical junction, referred as the CR4/5 domain in vertebrates (5) (6) (7) . The pseudoknot and CR4/5 domains are essential for telomerase activity and bind independently to two distinct TERT domains, TEN and TRBD, respectively (8-10).
The TRBD primary sequence from all known species contains three highly conserved motifs: CP, QFP and T (11, 12) . The vertebrate TRBD contains an additional vertebrate-specific RNA binding (VSR) motif (9) . Substitution and deletion studies found CP, QFP, T, and VSR motifs are required for CR4/5 binding in vertebrates (9, 13, 14) . In budding yeast, the TR contains a conserved three-way junction structure that is similar to the vertebrate CR4/5 domain but does not appear to bind TRBD in vitro (15) . The ciliate TR lacks a three-way junction but contains the conserved stem-loop IV that binds TRBD and might function analogously to the vertebrate CR4/5 domain (16) (17) (18) (19) (20) (21) . Although the structures of TRBD from Tetrahymena thermophila and Tribolium castaneum (red flour beetle) have been determined by X-ray crystallography (22, 23) , the details of the TR-TRBD binding interface remain elusive.
In this study, we map the binding interface between the TR-CR4/5 domain and the TERT-TRBD from the teleost fish Oryzias latipes (Japanese medaka). Medaka has the smallest known vertebrate TR of only 312 nt and a highly compact CR4/5 structure (24). Through 5-iodouridine (5IU) mediated cross-linking, the in vitro transcribed CR4/5 RNA fragment can efficiently and specifically cross-link to recombinant medaka TRBD protein. By mapping the cross-linking residues, we determined the RNAprotein binding interface with single-residue resolution.
Results
To map the RNA-protein binding interface, we established a largescale CR4/5-TRBD in vitro assembly system, consisting of purified TRBD protein and CR4/5 RNA fragments ( Fig. 1 A and B) . Recombinant medaka TRBD was overexpressed in Escherichia coli and purified as a fusion protein containing an N-terminal maltosebinding protein (MBP) tag for affinity purification (Fig. 1C) . The RNA-binding affinity of the MBP-TRBD fusion protein was determined by a gel-mobility shift assay. The gel-mobility of the radiolabeled CR4/5 RNA fragment was retarded in the presence of MBP-TRBD (Fig. 1D) . Using a filter-binding assay under a high-salt condition, we measured the K d of recombinant MBP-TRBD to wild-type CR4/5 RNA as 0.55 AE 0.06 μM (Fig. 1E ). Both the medaka CR4/5 RNA mutant lacking the conserved U bulge in the P6 stem and a human CR7 RNA fragment had no significant binding to MBP-TRBD ( Fig. 1 A and E) . We thus conclude the CR4/5-TRBD binding is specific and requires an intact CR4/5 structure.
We mapped the RNA-protein binding interface using a photoreagent-mediated cross-linking approach. The CR4/5 RNA containing photoaffinity cross-linker was prepared by in vitro T7 transcription in the presence of UTP and 5IU-5′-triphosphate at a ratio of 9∶1 for partial and random labeling. Upon UV irradiation, the cross-linker 5IU becomes highly reactive and forms a covalent bond to an adjacent atom, typically from an aromatic amino acid (25) . The 5IU-labeled CR4/5 RNA and TRBD protein fragments were assembled in vitro and irradiated with 302-nm UV light to generate RNA-protein cross-linked products ( Fig. 2A, lanes 2-4) . The cross-linked products were sensitive to trypsin protease treatment, indicating RNA-protein conjugates ( Fig. 2A, lanes 4 and 5) . The 5IU-mediated cross-linking generated a major product with an efficiency near 5% (Fig. 2A, lane 4 indicated by triangle). In contrast, a mock reaction using non-5IU RNA failed to generate this product ( Fig. 2A, compare lanes 4 and  7) . Incubation of TRBD protein with 4 μM tRNA, a nonspecific competitor, prior to CR4/5 binding did not reduce cross-linking efficiency (Fig. 2B, lane 3) . Moreover, 5IU-labeled human CR7 RNA fragment also failed to cross-link to the medaka TRBD (Fig. 2B, lanes 4-6) . Thus, the 5IU-mediated CR4/5-TRBD crosslinking was highly specific.
Alkaline partial hydrolysis was utilized to identify the crosslinking residues in the CR4/5 RNA. In this assay, the 5′-end 32 P-labeled RNA-protein conjugates were treated with a mild alkali, sodium carbonate, producing randomly cleaved RNA fragments. The largest radiolabeled non-peptide-linked RNA fragment in the ladder represented a product from the cleavage at the phosphodiester bond between the cross-linking and the 5′ neighboring nucleotides (Fig. 2C, denoted by −1) . The partial hydrolysis analysis of the RNA-protein conjugates identified two cross-linking RNA residues, U182 and U205 (Fig. 2D) . Reciprocal analysis using the 3′-end 32 P-labeled RNA-protein conjugates further confirmed both U182 and U205 as cross-linking residues (Fig. S1 ). In the secondary structure of the medaka CR4/5 domain, residues U182 and U205 are unpaired and would have the 5IU-labeled bases available for cross-linking to TRBD (Fig. 2E) .
To determine the contribution of U182 and U205 for binding TRBD, the dissociation constant (K d ) of mutant CR4/5 RNAs, U182C and U205A/G207C, were each measured using filterbinding assay (Fig. S2) . The U205A/G207C mutation was chosen for comparison to a similar double mutation in mouse TR that was previously found to have no effect on TERT binding (6) . Similarly, the U205A/G207C mutation in medaka TR did not decrease binding affinity to the TRBD (Fig. S2) . In contrast, mutation U182C slightly decreased binding affinity with an increased K d of 1.4 μM from 0.55 μM (Fig. S2) . Deletion of the U182 bulge drastically reduced binding affinity to near-background level. Thus, the U182 bulge is essential for TRBD binding.
To identify the amino acids cross-linked to U182 and U205, we employed MS to identify trypsinized TRBD peptides that were covalently linked to the RNA. RNA-protein conjugates were affinity-purified by the 6xHis tag at the C terminus of the recombinant MBP-TRBD using nickel-nitrilotriacetate agarose resin (Fig. S3A) . Under denaturing conditions, this affinity purification step removed free un-cross-linked RNA. The MBP-TRBD protein was then digested with trypsin protease to generate small peptides. The RNA-peptide conjugates were gel-purified and digested with either RNase A or T1. The resulting oligonucleotidepeptide conjugates were then suitable for MALDI-TOF MS. A reference spectrum for MS analysis was generated from non-crosslinked (mock) RNA that was also RNase-treated and analyzed in parallel.
MALDI-TOF analysis of the RNase T1 digested RNA-peptide conjugate generated a single prominent peak at 2,380.1 Da (Fig. 3A) . This peak was absent from the mock RNA reference spectrum, indicating a peptide-linked RNA fragment (Fig. 3A , compare upper and lower panels). Mass calculation of all possible combinations of trypsin-digested peptides and RNase T1-digested RNA fragments matched the 2,380.1-Da peak to peptide 496 FPPSELAYR 504 and RNA fragment 5 0 -U 182 CAG-3 0 (Fig. 3C ). Similar analysis of the RNaseA-treated sample identified two peaks at 2,091.1 and 2,395.9 Da, matching the same peptide 496 FPPSELAYR 504 cross-linked to RNA fragments 5 0 -GGU 182 -3 0 and 5 0 -GGU 182 C-3 0 , respectively ( Fig. S3 B and D) . The larger 5′-GGU182C-3′ fragment resulted from RNase A failing to cleave 3′ of U182, presumably due to the steric hindrance from the linked peptide. Mutation U182C eliminated the predominant 496 FPPSELAYR 504 peptide peak, further confirming the cross-linking of U182 to this peptide. The U182C mutation increased the yield of the U205 cross-linked product. MALDI-TOF analysis of the U205 cross-linked peptide found the 470 ISVAELMWK 478 peptide linked to an RNase T1-generated RNA fragment 5 0 -UU 205 CG-3 0 (Fig. 3 B and C) . Analysis of the RNaseA-treated RNA sample confirmed the result from the RNase T1-treated sample ( Fig. S3 C and D) .
To identify the specific amino acids cross-linked to 5IU, we carried out MALDI-TOF/TOF tandem MS sequencing to detect collision-induced dissociation of amino acids and their derivatives from the parental peptide. Prior to MALDI-TOF/TOF analysis, the RNA-peptide sample was treated with alkali and phosphatase, generating peptides linked to a single uridine nucleoside.
The U182-linked peptide 496 FPPSELAYR 504 has a mass of 1,321.61 Da (Fig. S4A) . The MS/MS analysis of this nucleotidepeptide conjugate determined Tyr503 as the amino acid covalently bonded to U182 (Fig. 4A) . The b-series ions from b 1 to b 7 had the expected peptide mass, whereas the b 8 ion had the increased mass of a uridine in addition to the tyrosine (Fig. 4A ). In the y series, the y 2 ion had a similar increase in mass from uridine and tyrosine.
The U205-linked peptide 470 ISVAELMWK 478 generated using the U182C mutant RNA had a mass of 1,318.63 Da (Fig. S4B) . The MS/MS analysis of this nucleotide-peptide conjugate identified Trp477 covalently bonded to U205 (Fig. 4B ). An additional peak was observed at 1,334.62 Da, which is 16 Da larger than the expected mass (Fig. S4B, Inset) . MS/MS analysis confirmed this was the same 470 ISVAELMWK 478 peptide but with an oxidized methionine accounting for the mass increase.
A third nucleotide-peptide conjugate peak was observed at 2,024.9 Da, which matched to the mass of the peptide 352 LVFFEGLPYLNGQER 366 and a uridine (Fig. S4A) . The MS/MS analysis of this peptide identified Phe355 as the crosslinked amino acid to an unidentified uridine from the CR4/5 RNA (Fig. 4C) . Alkaline partial hydrolysis and MALDI-TOF analysis of the trypsin/RNase-treated conjugate failed to identify the third cross-linking nucleotide, presumably due to the large size of the peptide (Fig. 3 and Fig. S3 ). Double-protease digestion using trypsin and chymotrypsin further cleaved the RNase T1-treated RNA-peptide conjugate to a single phenylalanine-RNA conjugate. MALDI-TOF analysis of this sample identified a 1,442.0-Da peak that matched to the mass of a single phenylalanine and an RNA fragment 5′-CUCG-3′ from loop L6 (Fig. S5 A-C) . This result suggests the U187 residue in loop L6 is the third cross-linking nucleotide. Moreover, CR4/5 RNA mutations that removed P5 or mutated the unpaired U residues in the three-way-junction did not eliminate the 2,025-Da peak of the U-linked peptide 352 LVFFEGLPYLNGQER 366 conjugate, further supporting U187 as the nucleotide cross-linking to Phe355 (Fig. S5 D-F) . The contribution of the cross-linking residues, Phe355, Trp477, and Tyr503, in binding the CR4/5 RNA was examined by mutagenesis. These aromatic residues were each substituted with an aromatic or nonaromatic amino acid, and analyzed for RNAbinding affinity. Mutants with aromatic substitutions, Trp477Phe and Tyr503Phe, retained wild-type RNA-binding affinity, whereas mutants with nonaromatic substitutions, Trp477Leu and Tyr503-Ser, showed reduced binding affinity (Fig. S6A) . For Phe355, substitutions Phe355Tyr and Phe355Leu both reduced RNA-binding affinity (Fig. S6A) . In the context of the full-length TERT protein, these mutations exhibited similar effects for CR4/5 RNA-binding affinity (Fig. S6B) . As expected, these TERT mutations did not affect pseudoknot RNA binding. Activity assay of these mutants showed reduced telomerase activity for the Phe355 and Tyr503 mutants, and reduced repeat addition processivity for the Trp477 mutant (Fig. S6C) . Because Trp477 is in close proximity to the L6.1 loop of CR4/5 RNA, we assayed the L6.1 mutant U205A/G207C for telomerase activity and processivity. The L6.1 mutation decreased telomerase activity but surprisingly increased repeat addition processivity (Fig. S6D) . These results indicate that these three amino acids are important for both CR4/5 RNA binding and telomerase activity.
Reciprocally, we determined the CR4/5 structural elements essential for binding TRBD. An array of CR4/5 RNA substitutions and truncations were examined by filter-binding assay (Fig. S7A) . The results suggest stems P6, P6.1, and loop L6 are important for binding TRBD (Fig. 5A and Fig. S7B ). In contrast, substitution of conserved nucleotides in L6.1 had no effect on binding TRBD (Fig. S7B, mutant M6) , which is consistent with a previous study on mouse TR (6). Truncations of CR4/5 RNA showed stem P5 is not necessary for TRBD binding (Fig. S7B, mutants M10-11 ), in accordance with a previous study that also showed P5 is dispensable for reconstituting telomerase activity in vitro (26) . The minimal RNA fragment that retained wild-type binding affinity is only 39 nt, spanning residue 176 to residue 214. Although the P5 stem is not essential, specific residues in the internal loop of the three-way helical junction are required for effective TRBD binding (Fig. S7B, mutants M11-15 ). This functional survey of RNA mutations and truncations determined the essential TRBD-binding region within the CR4/5 domain (Fig. 5A) .
To predict positions on the TERT structure, residues Trp477, Tyr503, and Phe355 were mapped onto a medaka TRBD struc- tural model (Fig. 5B ). This homology model was generated by threading the medaka sequence through the Tetrahymena TRBD crystal structure (Fig. S8 A-D) . It is noted that the actual medaka structure may differ from either the Tetrahymena structure or medaka threading-based TRBD model. Nonetheless, superimposition of the Tetrahymena structure and the medaka model with the Tribolium TERT structure suggested similar protein folds for all three structures (Fig. S8 E and F) . Moreover, based on sequence alignment and secondary structure prediction, Trp477 and Tyr503 were mapped to similar positions on both Tetrahymena and Tribolium TRBD structures. In comparison, the third residue Phe355 is located in the vertebrate-specific VSR motif, making the prediction of its position in the structure more difficult (Fig. S8 C-E) . Both the Tetrahymena and Tribolium structures, as well as the medaka model, have a positively charged surface patch where the CR4/5 cross-linking amino acids are located (Fig. S8D) . The positions of these cross-linked residues in relation to the RT and CTE domains are shown on a combined model that superimposed the medaka TRBD model and Tribolium TERT structures (Fig. S8E) . The TRBD structural models together with the mapped CR4/5 binding surface provide useful insights into the role of CR4/5-TRBD interaction in telomerase function.
Discussion
Functional assembly of the vertebrate telomerase RNP relies on specific RNA-protein interactions between TR and TERT (6, 24, 27) . The template-pseudoknot domain binds to the TEN domain, positioning the template within the TERT active site, and defines the template boundary (10, 28, 29) . The CR4/5 domain binds to the TRBD with a critical yet enigmatic function for enzymatic activity. Mutagenesis and functional analyses have suggested several possible functions for CR4/5-TRBD binding: facilitating a conformational activation of TRBD (18), interacting with RNA template (30), or enhancing enzymatic catalysis (6, 27, 31) . Our photoaffinity cross-linking analysis has defined the CR4/5-TRBD binding interface, providing insight into the assembly of the telomerase RNP and the function of the critical CR4/5 domain. The CR4/5 elements required for TRBD binding include: stems P6 and P6, loop L6, and the three-way-junction internal loop (Fig. S7) . The single-nucleotide U182 bulge in P6.1 and the 5-nucleotide loop L6.1 are structural features universally conserved in all known vertebrate TRs, suggesting crucial roles in telomerase function (7, 24) . The U182 bulge within stem P6 is essential for TRBD binding because deletion of this residue nearly abolishes binding affinity (Figs. S2 and S7B) . However, deletion of this bulge may also affect the tertiary structure of the entire stem loop and thus reduce TRBD binding. Although our cross-linking data do not provide direct evidence for physical interactions, they outline the RNA-protein binding interface between CR4/5 and TRBD.
Stem-loop 6.1 is the most highly conserved element in the CR4/5 domain (7, 24) . Stem P6.1 is essential for TRBD binding, whereas loop L6.1 is not (Fig. S7B) . Although the cross-linking data indicate U205 and Trp477 are in immediate proximity, these two residues may not form critical contacts. Loop L6.1 is highly conserved in all vertebrates and crucial for telomerase activity and repeat addition processivity (Fig. S6D) . Mapping the U205 cross-linked amino acid Trp477 onto the medaka TRBD model places L6.1 in close proximity to the adjoining CTE domain and distant from the catalytic RT domain (Fig. 5B) . We therefore conclude that L6.1 does not directly participate in catalysis. Instead, the position of this loop suggests that this structure may facilitate functional folding of TERT through a putative interaction with CTE. This putative L6.1-CTE interaction may be required for functional folding or assembly of active telomerase RNP, which would explain the requirement of CR4/5 for reconstituting telomerase activity (Fig. S6D, lane 2) . Because mutations in the CTE domain affect repeat addition processivity (32, 33) , the altered processivity of the Trp477Leu and L6.1 (U205A/G207C) mutants are potentially mediated by this putative L6.1-CTE interaction. A recent study suggested that, in human telomerase, the TRBD and CTE domains interact in the absence of TR (28) . However, CR4/ 5 might provide additional and crucial interactions to CTE for proper positioning of the CTE domain and optimal assembly of the telomerase RNP.
The spacing of the three cross-linked residues in TRBD together with the secondary structure of CR4/5 provides a glimpse to the tertiary orientation of stems P6 and P6.1. Measuring within the two known structures and a medaka threading-based model of TRBD, the two cross-linking sites of U182 and U205 are separated by only 15-20 Å (Fig. 5B) , suggesting that the U bulge of P6 and L6.1 are close to each other, requiring a sharp turn at the junction (Fig. 5A ). This evidence argues against a coaxial stacking of these two helices as suggested in previous reports (34, 35) .
The highly conserved TRBD motifs, QFP, CP, and T, have little overlap with the CR4/5 binding surface (Fig. S8C) , suggesting that these motifs have other functions than binding the CR4/5 RNA. Motif T is part of the T pocket, a previously proposed RNA-binding site that has a positively charged surface (22) . The T pocket is located near the active site and potentially interacts with the RNA template and/or template boundary elements. In support of this interaction, mutations in motif T affect the repeat addition rate (36) . The U182 cross-linked residue Trp477 participates in RNA binding and is located at the C terminus of motif QFP (Fig. S8 A and C) . The remaining QFP may stabilize protein folding, as suggested by the Tribolium TERT structure (23) . Motif CP is located opposite the CR4/5 binding pocket (Fig. S8C) . Deletion of this motif completely abolishes telomerase activity, whereas RNA binding is only slightly reduced (9) . The vertebrate-specific motif VSR contains the third cross-linked residue Phe355 and is part of the CR4/5 binding pocket. However, VSR may interact with a vertebrate-specific TR element and may not be conserved in other species. In general, there is less sequence conservation in the CR4/5 binding interface than in the three motifs, CP, QFP, and T, presumably because of a rapid coevolution of the TERT with the divergent TR.
The integral RNA component and its interacting protein domains are unique features that distinguish the telomerase RNP from retrotransposons. Mapping the RNA-protein binding interface between the CR4/5 and TRBD provides important clues for the assembly of TR and TERT into a functional RNP, and a potential function for the essential CR4/5 domain. Moreover, the methodology developed in this study for mapping a telomerase RNA-protein binding interface can be adapted and applied to other species, as well as other RNP complexes.
Materials and Methods
Protein Expression and Purification. A synthetic medaka RNA-binding domain (TRBD) gene (encoding for amino acids 318-579) was cloned into pMAL-2CX (New England Biolabs) generating plasmid pMBP-TRBD-6xHis. The recombinant protein gene was expressed in ScarabXpress T7lac cells (Scarab Genomics). Cells were lysed by sonication in 1× column buffer [50 mM Tris·HCl (pH 7.5), 500 mM NaCl, 1 mM MgCl 2 10% glycerol, and 1 mM tris(2-carboxyethyl)phosphine (TCEP)] supplemented with 1 mM PMSF and 1× complete protease inhibitor cocktail (Roche). Lysate was centrifuged at 18;000 × g for 15 min followed by 55% ammonium sulfate precipitation. The pellet was resuspended in 1× column buffer, applied to amylose resin (New England Biolabs) and eluted with 10 mM maltose. Peak fractions were pooled and applied to a gel filtration column (Sephadex 200; GE). Eluted MBP-TRBD monomer was used for further studies.
Gel-Mobility Shift Assay. Equal molar 32 P 5′-labeled CR4/5 RNA and purified MBP-TRBD fusion protein were mixed at 0.8 μM and incubated in 20 μL column buffer at room temperature for 30 min. Ten microliters of the binding reaction was loaded onto a native polyacrylamide gel [5% acrylamide:bisacrylamide (29∶1), 0.5× TBE (45 mM Tris·HCl, 45 mM boric acids, and 1 mM EDTA, pH 8.0), 5% glycerol, and 1 mM MgCl 2 ] for electrophoresis, and the dried gel was exposed to a storage phosphor screen for image analysis with PhosphorImager FX-Pro (BioRad).
Filter-Binding Assay. Radiolabeled RNA (ca. 0.5 nM) was incubated with purified MBP-TRBD protein from 50 nM to 5 μM in 1× binding buffer [50 mM Tris·HCl (pH 7.5), 500 mM NaCl, 1 mM MgCl 2 10% glycerol, and 1 mM TCEP) at room temperature for 30 min. Aliquots of the RNA-protein mixtures were applied onto prewashed 0.2 μM Protran (BA83) nitrocellulose membranes (Whatman) on a 1225 Sampling Manifold (Millipore) under vacuum. The membranes were washed once with 1 mL 1× binding buffer. The dried membranes were exposed to a storage phosphor screen and analyzed using the Molecular Imager FX-Pro (BioRad). Intensity of RNA bound on each membrane was quantitated by Quantity One software (BioRad) and normalized to the input RNA. Binding titrations were performed in triplicate. K d and SEM were determined using the one-site-specific binding function in Prism 5 (GraphPad Software).
Photoaffinity Cross-linking Analysis and RNA Cross-linking Residue Identification. RNA was in vitro transcribed in the presence of UTP and 5-iodouridine 5′-triphosphate (Trilink) at a ratio of 9∶1, gel extracted, and 5′ radiolabeled by 32 P-γ-ATP and T4 polynucleotide kinase (New England Biolabs). Two nanograms of RNA and approximately 23 μg of MBP-TRBD protein were incubated on ice for 30 min in 50 μL of 1× binding buffer [50 mM Tris·HCl (pH 7.5), 500 mM NaCl, 1 mM MgCl 2 10% glycerol, and 1 mM tris(2-carboxyethyl)phosphine], and then irradiated with 302-nm UV light for 2 h. The sample was then electrophoresed on an 8% SDS gel followed by autoradiography. The cross-linking residues in the RNA were identified using alkaline partial hydrolysis as previously described with minor modifications (37) . In brief, gel slices containing the cross-linked RNA were excised, washed three times with 1 mL water, and incubated in 100 μL hydrolysis buffer [100 mM sodium carbonate (pH 9.5) and 1 mM EDTA] for 5 min at room temperature and 10 min at 90°C. Reaction was neutralized by 200 μL of 100 mM Tris·HCl (pH 7.5), and RNA was eluted overnight and ethanol precipitated. Partially hydrolyzed RNA fragments were resolved on a denaturing 10% polyacrylamide sequencing gel along with both RNase T1-digested and alkaline-hydrolyzed RNA ladders.
Additional materials and methods for TRBD protein purification, filterbinding assay, telomerase activity assay, and cross-linking residue identification using mass spectrophotometry are described in SI Materials and Methods.
